-
1.Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists 失效
标题翻译: 吡啶,嘧啶,喹啉,喹唑啉和萘脲素受体拮抗剂公开(公告)号:US07265122B2
公开(公告)日:2007-09-04
申请号:US10783916
申请日:2004-02-20
申请人: Chengde Wu , C. Eric Anderson , Huong Bui , Brian Dupre , Daxin Gao , George W. Holland , Jamal Kassir , Wen Li , Junmei Wang
发明人: Chengde Wu , C. Eric Anderson , Huong Bui , Brian Dupre , Daxin Gao , George W. Holland , Jamal Kassir , Wen Li , Junmei Wang
IPC分类号: C07D401/02 , A61K31/47
CPC分类号: C07D215/44 , C07D401/12 , C07D401/14
摘要: The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.
摘要翻译: 本发明涉及尿素调节素II受体拮抗剂,含有它们的药物组合物及其用途。
-
2.Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists 失效
标题翻译: 吡啶,嘧啶,喹啉,喹唑啉和萘脲素受体拮抗剂公开(公告)号:US20050054850A1
公开(公告)日:2005-03-10
申请号:US10924181
申请日:2004-08-23
申请人: Chengde Wu , C. Anderson , Huong Bui , Brian Dupre , Daxin Gao , George Holland , Jamal Kassir , Wen Li , Junmei Wang
发明人: Chengde Wu , C. Anderson , Huong Bui , Brian Dupre , Daxin Gao , George Holland , Jamal Kassir , Wen Li , Junmei Wang
IPC分类号: A61K31/503 , A61K31/513 , A61K31/5377 , C07D413/14 , C07D43/14 , C07D41/14
CPC分类号: A61K31/503 , A61K31/513 , A61K31/5377 , C07D413/14
摘要: The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.
摘要翻译: 本发明涉及尿素调节素II受体拮抗剂,含有它们的药物组合物及其应用。
-
3.Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists 失效
标题翻译: 苯二胺尿激肽素受体拮抗剂和CCR-9拮抗剂公开(公告)号:US20050049286A1
公开(公告)日:2005-03-03
申请号:US10924180
申请日:2004-08-23
申请人: Chengde Wu , C. Anderson , Huong Bui , Daxin Gao , Jamal Kassir , Wen Li , Junmei Wang , Ronald Biediger , Jie Chen , Robert Market
发明人: Chengde Wu , C. Anderson , Huong Bui , Daxin Gao , Jamal Kassir , Wen Li , Junmei Wang , Ronald Biediger , Jie Chen , Robert Market
IPC分类号: A61K31/40 , A61K31/44 , A61K31/445 , A61K31/495 , A61K31/537 , A61K31/55 , C07D211/26 , C07D265/30
CPC分类号: C07D207/16 , A61K31/16 , A61K31/40 , A61K31/445 , A61K31/497 , C07D209/08 , C07D209/44 , C07D213/74 , C07D237/08 , C07D239/26 , C07D241/42 , C07D295/135 , C07D333/38 , C07D401/12 , C07D403/12 , C07D409/12
摘要: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
摘要翻译: 本发明涉及尿素调节素II受体拮抗剂,CCR-9拮抗剂,含有它们的药物组合物及其应用。
-
4.Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists 审中-公开
标题翻译: 吡啶,嘧啶,喹啉,喹唑啉和萘脲素受体拮抗剂公开(公告)号:US20080004312A1
公开(公告)日:2008-01-03
申请号:US11807047
申请日:2007-05-25
申请人: Eric Anderson , Brian Dupre , Daxin Gao , Raymond Kessler , Wen Li , Chengde Wu
发明人: Eric Anderson , Brian Dupre , Daxin Gao , Raymond Kessler , Wen Li , Chengde Wu
IPC分类号: A61K31/4709 , A61P1/04 , A61P11/00 , A61P19/02 , A61P21/00 , A61P43/00 , A61P9/10 , C07D215/44
CPC分类号: C07D215/44 , C07D401/12 , C07D401/14
摘要: The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.
摘要翻译: 本发明涉及尿素调节素II受体拮抗剂,含有它们的药物组合物及其用途。
-
5.
公开(公告)号:US07320989B2
公开(公告)日:2008-01-22
申请号:US10924181
申请日:2004-08-23
申请人: Eric Anderson , Brian Dupre , Daxin Gao , Raymond J. Kessler , Wen Li , Chengde Wu
发明人: Eric Anderson , Brian Dupre , Daxin Gao , Raymond J. Kessler , Wen Li , Chengde Wu
IPC分类号: A61K31/44 , C07D215/38 , C07D211/72
CPC分类号: A61K31/503 , A61K31/513 , A61K31/5377 , C07D413/14
摘要: The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.
-
6.Propanoic acid derivatives that inhibit the binding of integrins to their receptors 失效
标题翻译: 抑制整联蛋白与其受体结合的丙酸衍生物公开(公告)号:US06723711B2
公开(公告)日:2004-04-20
申请号:US09973414
申请日:2001-10-09
申请人: Ronald J. Biediger , Brian Dupre , Linda K. Hamaker , George W. Holland , Jamal M. Kassir , Wen Li , Robert V. Market , Noel Nguyen , Ian L. Scott , Chengde Wu , E. Radford Decker
发明人: Ronald J. Biediger , Brian Dupre , Linda K. Hamaker , George W. Holland , Jamal M. Kassir , Wen Li , Robert V. Market , Noel Nguyen , Ian L. Scott , Chengde Wu , E. Radford Decker
IPC分类号: C07D21364
CPC分类号: C07D213/64 , C07D317/60 , C07D405/12 , C07D409/14
摘要: A compound of the structure A method for the inhibition of the binding of &agr;4&bgr;1 integrin to its receptors, for example VCAM-1(vascular cell adhesion molecule-1) and fibronectin; pharmaceutically active compositions comprising these compounds; and the use of these compounds for the control or prevention of diseases states in which &agr;4&bgr;1 is involved are also disclosed.
摘要翻译: 用于抑制α4β1整联蛋白与其受体结合的方法的化合物,例如VCAM-1(血管细胞粘附分子-1)和纤连蛋白; 包含这些化合物的药物活性组合物; 并且还公开了这些化合物用于控制或预防其中涉及α4β1的疾病状态的用途。
-
7.
公开(公告)号:US06262084B1
公开(公告)日:2001-07-17
申请号:US09417886
申请日:1999-10-14
申请人: Ronald J. Biediger , Vanessa O. Grabbe , George W. Holland , Jamal Kassir , Karin M. Keller , Timothy P. Kogan , Shuqun Lin , Robert V. Market , Bore G. Raju , Ian L. Scott , Chengde Wu
发明人: Ronald J. Biediger , Vanessa O. Grabbe , George W. Holland , Jamal Kassir , Karin M. Keller , Timothy P. Kogan , Shuqun Lin , Robert V. Market , Bore G. Raju , Ian L. Scott , Chengde Wu
IPC分类号: A61K31192
CPC分类号: C07D417/14 , C07D317/60 , C07D333/20 , C07D333/24 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/14
摘要: A method for the inhibition of the binding of &agr;4&bgr;1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions thereof; and the use of the compounds either as above, or in formulations for the control or prevention of diseases states in which &agr;4&bgr;1 is involved.
摘要翻译: 抑制α4β1整联蛋白与其受体结合的方法,例如VCAM-1(血管细胞粘附分子-1)和纤连蛋白; 抑制这种结合的化合物; 其药物活性组合物; 以及如上所述的化合物或用于控制或预防涉及α4β1的疾病状态的制剂中的用途。
-
8.Carboxylic acid derivatives that inhibit the binding of integrins to their receptors 有权
标题翻译: 抑制整联蛋白与其受体结合的羧酸衍生物公开(公告)号:US20060276476A1
公开(公告)日:2006-12-07
申请号:US11152695
申请日:2005-06-14
申请人: Ronald Biediger , Qi Chen , E. Decker , George Holland , Jamal Kassir , Wen Li , Robert Market , Ian Scott , Chengde Wu , Jian Li
发明人: Ronald Biediger , Qi Chen , E. Decker , George Holland , Jamal Kassir , Wen Li , Robert Market , Ian Scott , Chengde Wu , Jian Li
IPC分类号: A61K31/50
CPC分类号: C07D213/75 , C07D215/22 , C07D221/04 , C07D221/16 , C07D237/22 , C07D239/47 , C07D317/60 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D471/04
摘要: A method for the inhibition of the binding of α4β1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which α4β1 is involved.
摘要翻译: 用于抑制α4A/β1整联蛋白与其受体例如VCAM-1(血管细胞粘附分子-1)和纤连蛋白的结合的方法; 抑制这种结合的化合物; 包含这些化合物的药物活性组合物; 以及上述或在制剂中使用这些化合物用于控制或预防涉及α4β1的疾病状态。
-
9.Carboxylic acid derivatives that inhibit the binding of integrins to their receptors 有权
标题翻译: 抑制整联蛋白与其受体结合的羧酸衍生物公开(公告)号:US06972296B2
公开(公告)日:2005-12-06
申请号:US09973142
申请日:2001-10-09
申请人: Ronald J. Biediger , Qi Chen , E. Radford Decker , George W. Holland , Jamal M. Kassir , Wen Li , Robert V. Market , Ian L. Scott , Chengde Wu , Jian Li
发明人: Ronald J. Biediger , Qi Chen , E. Radford Decker , George W. Holland , Jamal M. Kassir , Wen Li , Robert V. Market , Ian L. Scott , Chengde Wu , Jian Li
IPC分类号: C07D221/04 , A61K31/435 , A61K31/44 , A61K31/4412 , A61K31/4704 , A61K31/495 , A61K31/50 , A61K31/505 , A61P1/00 , A61P3/10 , A61P9/10 , A61P11/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/08 , C07D207/416 , C07D211/86 , C07D213/02 , C07D213/62 , C07D213/69 , C07D213/72 , C07D213/75 , C07D215/22 , C07D215/38 , C07D221/16 , C07D237/16 , C07D237/22 , C07D239/28 , C07D239/46 , C07D239/47 , C07D317/46 , C07D317/60 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/06 , C07D413/12 , C07D417/06 , C07D471/04 , C07D498/04 , C07K14/78 , C07D211/72
CPC分类号: C07D213/75 , C07D215/22 , C07D221/04 , C07D221/16 , C07D237/22 , C07D239/47 , C07D317/60 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D471/04
摘要: A method for the inhibition of the binding of α4β1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which α4β1 is involved.
摘要翻译: 用于抑制α4A/β1整联蛋白与其受体例如VCAM-1(血管细胞粘附分子-1)和纤连蛋白的结合的方法; 抑制这种结合的化合物; 包含这些化合物的药物活性组合物; 以及上述或在制剂中使用这些化合物用于控制或预防涉及α4β1的疾病状态。
-
10.Carboxylic acid derivatives that inhibit the binding of integrins to their receptors 有权
标题翻译: 抑制整联蛋白与其受体结合的羧酸衍生物公开(公告)号:US07812038B2
公开(公告)日:2010-10-12
申请号:US11152695
申请日:2005-06-14
申请人: Ronald J. Biediger , Qi Chen , E. Radford Decker , George W. Holland , Jamal M. Kassir , Wen Li , Robert V. Market , Ian L. Scott , Chengde Wu , Jian Li
发明人: Ronald J. Biediger , Qi Chen , E. Radford Decker , George W. Holland , Jamal M. Kassir , Wen Li , Robert V. Market , Ian L. Scott , Chengde Wu , Jian Li
IPC分类号: A61K31/4412
CPC分类号: C07D213/75 , C07D215/22 , C07D221/04 , C07D221/16 , C07D237/22 , C07D239/47 , C07D317/60 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D471/04
摘要: A method for the inhibition of the binding of α4β1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which α4β1 is involved.
摘要翻译: 抑制α4和bgr1整联蛋白与其受体例如VCAM-1(血管细胞粘附分子-1)和纤连蛋白的结合的方法; 抑制这种结合的化合物; 包含这些化合物的药物活性组合物; 以及使用上述化合物或用于控制或预防涉及α4和bgr1的疾病状态的制剂。
-
-
-
-
-
-
-
-
-